Last reviewed · How we verify
Revefenacin Inhalation Solution
At a glance
| Generic name | Revefenacin Inhalation Solution |
|---|---|
| Also known as | Yupelri |
| Sponsor | Mylan Pharma UK Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Revefenacin in Acute Respiratory Insufficiency in COPD (PHASE2)
- Phase 4 COPD and Suboptimal Inspiratory Flow Rate (PHASE4)
- Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD) (PHASE3)
- Fasting Bioavailability Study of Mylan's Revefenacin Inhalation Solution (PHASE1)
- A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |